Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.37 |
| ▸ | KLK7 | P49862 | 2/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17283437 | 0.93 | MAPK1 (0.42) | TGM2TACR1HTTLMNASMN1; SMN2 | |
| SCHEMBL18875834 | 0.92 | TGM2 (0.40) | TGM2TACR1HTTLMNASMN1; SMN2 | |
| SCHEMBL18875837 | 0.91 | TGM2 (0.39) | TGM2TACR1HTTLMNASMN1; SMN2 | |
| SCHEMBL18875829 | 0.89 | TGM2 (0.43) | TGM2TACR1HTTLMNASMN1; SMN2 | |
| SCHEMBL17283436 | 0.88 | KEAP1 (0.40) | TGM2TACR1HTTLMNASMN1; SMN2 | |
| SCHEMBL18875849 | 0.87 | TGM2 (0.42) | TGM2TACR1HTTLMNASMN1; SMN2 | |
| SCHEMBL17283442 | 0.85 | CA1 (0.36) | TGM2TACR1HTTKLK7KLK5 | |
| SCHEMBL24294564 | 0.83 | LMNA (0.47) | HTTLMNASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL17283402 | 0.82 | MAPK1 (0.37) | TACR1MAPK1 | |
| SCHEMBL17283441 | 0.80 | MAPK1 (0.60) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | TGM2 569/4885TACR1 3018/4885HTT 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.